Clinical Trials · NCT03959865

GLP-1 REceptor Agonists and Real World EvIdeNce

UnknownN/ALiraglutide (Unclear)Dulaglutide (Unclear)Exenatide (Unclear)Lixisenatide (Unclear)
Phase
N/A
Recruitment status
Unknown
Sponsor
University of Padova
Enrollment
6,000
Start date
Dec 2018
Locations
6 sites, Italy
Primary endpoint
HbA1c
View Liraglutide compound reference